Page 1

CARIBOU BIOSCIENCES Caribou Biosciences Provides Business Update and Reports Second Quarter 2021 Financial Results September 2 , 2021 Completed upsized initial public offering of common stock , raising $ 349.6 million in gross proceeds including full exercise of underwriters ' option to purchase additional shares ANTLER Phase 1 clinical trial of CB - 010 in relapsed or refractory B cell non - Hodgkin lymphoma ongoing Expanded company's board of directors with appointment of Nancy Whiting , Pharm.D . BERKELEY , Calif . , Sept. 02 , 2021 ( GLOBE NEWSWIRE ) -- Caribou Biosciences , Inc. ( Nasdaq : CRBU ) , a leading clinical - stage CRISPR genome- editing biopharmaceutical company , today reported business highlights and financial results for the second quarter of 2021 . " 2021 has been a transformational year for Caribou , and we believe that our highly successful IPO speaks to the enormous potential of the company's chRDNA technology to deliver innovative , transformative therapies for patients with devastating diseases , " said Rachel Haurwitz , Ph.D. , Caribou's president and chief executive officer . " In July , we announced the dosing of the first patient in our ANTLER Phase 1 clinical trial evaluating our lead product candidate , CB - 010 , in relapsed or refractory B cell non - Hodgkin lymphoma . In addition to this program , we have three other wholly - owned allogeneic cell therapy product candidates in our pipeline , and we are collaborating with AbbVie to research and develop two additional allogeneic CAR - T programs for AbbVie using our Cas12a chRDNA technology . " Business Highlights Dosed the first patient in Phase 1 clinical trial of CB - 010 . In July 2021 , Caribou reported dosing the first patient in its ANTLER Phase 1 clinical trial of CB - 010 . The ANTLER trial is evaluating CB - 010 in patients with relapsed or refractory B cell non - Hodgkin lymphoma ( B - NHL ) , and initial data from the trial are expected in 2022 . Completed upsized IPO raising $ 349.6 million in gross proceeds . In July 2021 , Caribou completed its IPO , selling 19,000,000 shares of its common stock at a price to the public of $ 16.00 per share , for gross proceeds of $ 304.0 million . In August 2021 , the underwriters fully exercised their option to purchase an additional 2,850,000 shares of common stock at the IPO price , increasing the total number of shares sold by Caribou in the IPO to 21,850,000 shares and the aggregate gross proceeds to $ 349.6 million . Aggregate net proceeds from the IPO , after deducting underwriting discounts and commissions and other offering expenses payable by Caribou , were $ 321.0 million . Expanded Caribou's board of directors . In August 2021 , Nancy Whiting , Pharm.D . , was appointed to Caribou's board of directors . Dr. Whiting , who most recently served as executive vice president , corporate strategy , alliances and communication of Seagen , Inc. , brings over 17 years of biotechnology industry expertise in drug and portfolio development as well as significant strategic leadership experience . Dr. Whiting joins Scott Braunstein , M.D. , Andrew Guggenhime , Rachel Haurwitz , Ph.D. , and Natalie Sacks , M.D. , on Caribou's board of directors . In July 2021 , Mr. Guggenhime assumed the roles of chair of the board of directors and chair of the audit committee . Published data demonstrating the significantly improved specificity of Caribou's proprietary CRISPR hybrid RNA - DNA ( chRDNA ) guide technology compared to all - RNA guides . In September 2021 , Caribou and its collaborators published studies in an article entitled , " Conformational control of Cas9 by CRISPR hybrid RNA - DNA guides mitigates off - target activity in T cells , " in the journal Molecular Cell . Upcoming Milestones CB - 010 : Caribou expects initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B - NHL in 2022. CB - 010 is an allogeneic anti - CD19 CAR - T cell therapy derived from healthy donor T cells engineered using Cas9 chRDNA technology to introduce a CD19 - specific CAR into the TRAC gene locus , thus eliminating expression of the T cell receptor to reduce the risk of graft versus host disease . The T cells are further modified to knock out the PDCD1 gene , preventing the expression of the PD - 1 protein , to boost the persistence of CAR - T cell antitumor activity . CB - 011 : Caribou expects to file an Investigational New Drug ( IND ) application for its CB - 011 program in 2022. CB - 011 is an allogeneic anti - BCMA CAR - T cell therapy derived from healthy donor T cells that is being developed as a potential treatment for relapsed or refractory multiple myeloma . Caribou is engineering healthy donor T cells using its proprietary Cas12a chRDNA technology to introduce a BCMA - specific CAR into the TRAC gene locus . In addition , Caribou utilizes an immune cloaking strategy designed to prevent rapid immune rejection of CB - 011 . This strategy comprises two edits : knockout of the endogenous B2M gene and site - specific insertion of a B2M - HLA - E fusion gene into the T cell genome . CB - 012 : Caribou expects to file an IND application for its CB - 012 program in 2023. CB - 012 is an allogeneic anti - CD371 CAR - T cell therapy derived from healthy donor T cells for the potential treatment of relapsed or refractory acute myeloid leukemia . CB - 012 cells are engineered using Caribou's proprietary Cas12a chRDNA technology to introduce a fully - human CD371 - specific CAR into the TRAC locus and to armor the cells to promote persistence . CB - 020 : Caribou expects to announce target selection for its CB - 020 program in 2022. CB - 020 , a CAR - NK product candidate , is the lead program in Caribou's proprietary genome - edited iPSC - derived natural killer ( iNK ) cell therapy platform . Multiplex - edited CAR - NKs hold significant potential for treating a variety of solid tumor types . Second Quarter 2021 Financial Results Cash and cash equivalents : Caribou finished the second quarter of 2021 with cash and cash equivalents of $ 129.5 million . Cash and cash